FORESEE PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.3 TWD | +0.53% |
|
-1.46% | -1.98% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 916M 28.25M | Sales 2025 * | - | Capitalization | 12.81B 395M |
|---|---|---|---|---|---|
| Net income 2024 * | -76M -2.34M | Net income 2025 * | - | EV / Sales 2024 * | 14.1 x |
| Net Debt 2024 * | 116M 3.58M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-147
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.79% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.53% | ||
| 1 week | -1.46% | ||
| Current month | -1.67% | ||
| 1 month | -5.13% | ||
| 3 months | -0.11% | ||
| 6 months | +11.47% | ||
| Current year | -1.98% |
1 week
93.30
96.20
1 month
93.10100.50
Current year
92.50107.50
1 year
75.30107.50
3 years
69.50141.00
5 years
35.10141.00
10 years
35.10141.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Hua Li
FOU | Founder | - | 15-07-08 |
Benjamin Chien
CEO | Chief Executive Officer | - | 13-02-07 |
Max Chan
DFI | Director of Finance/CFO | 56 | 19-10-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Lee
BRD | Director/Board Member | 73 | 15-08-02 |
Benjamin Chien
CEO | Chief Executive Officer | - | 13-02-07 |
Fu Shiow Yin
BRD | Director/Board Member | - | 16-03-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 94.3 | +0.53% | 178,259 |
| 24-05-09 | 93.8 | -0.64% | 241,183 |
| 24-05-08 | 94.4 | 0.00% | 153,808 |
| 24-05-07 | 94.4 | -0.21% | 135,993 |
| 24-05-06 | 94.6 | -1.15% | 509,757 |
End-of-day quote Taipei Exchange, May 09, 2024
More quotes
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
94.3
TWD
Average target price
153
TWD
Spread / Average Target
+62.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.98% | 395M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 6576 Stock
